Royal Society of Chemistry, Organic and Biomolecular Chemistry, 17(18), p. 3288-3296, 2020
DOI: 10.1039/c9ob02682g
Full text: Unavailable
Recurrence and drug resistance are major challenges in the treatment of acute myeloid leukemia (AML) that spur efforts to identify new clinical targets and active agents.